NDAOPHTHALMICSOLUTION/DROPS
Approved
Aug 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HUMORSOL (demecarium bromide) is an ophthalmic solution approved in 1959 for glaucoma and accommodative esotropia by reducing intraocular pressure through cholinergic mechanisms. It is a long-acting anticholinesterase agent administered as eye drops. The drug works by inhibiting acetylcholinesterase, increasing parasympathetic tone in the eye.
LOE Approaching
With LOE approaching and minimal linked job postings, the commercial team supporting this legacy product is likely small and focused on maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HUMORSOL offers limited career growth potential given its LOE-approaching status, zero linked job postings, and minimal competitive differentiation. This role would suit professionals focused on portfolio maintenance, legacy brand stewardship, or transition into other therapeutic areas.
Brand ManagerField Sales Representative
Worked on HUMORSOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.